Objective: To evaluate sleep-related effects in patients with epilepsy newly initiated on brivaracetam (BRV) monotherapy in a tertiary care hospital in South India. Methods: In this prospective analytical study, 46 patients aged ≥12 years with newly diagnosed epilepsy were enrolled. Patients received BRV monotherapy (50–100 mg twice daily; pediatric dose: 0.75–1.5 mg/kg twice daily). Sleep-related adverse events were recorded, and patients were assessed at baseline and one month using the Epworth Sleepiness Scale – Indian version (ESS-I), Pittsburgh Sleep Quality Index (PSQI), Insomnia Severity Index (ISI), and a one-month sleep log. Paired t-tests and McNemar’s exact test were used to compare baseline and follow-up measures. Results: The mean age was 37.8 ± 11.9 years; 47.8% were male. The majority had generalized epilepsy (69.6%) and duration of epilepsy 10 hours/day increased from 4.3% to 17.4% (p = 0.031). Daytime sleep >1 hour/day increased from 6.5% to 21.7% (p = 0.002). No patients discontinued BRV due to adverse effects. Conclusion: BRV monotherapy is associated with mild increases in daytime sleepiness and sleep duration without serious adverse events. BRV appears safe and well-tolerated in newly diagnosed epilepsy, with manageable effects on sleep. Larger studies with long-term follow-up are needed.